April 24, 2017
Bayer parners up with Goodbye Malaria to end malaria
Bayer has partnered up with Goodbye Malaria to support the objectives of Ending Malaria for Good in Southern Africa.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
April 24, 2017
Lilly’s breast cancer drug study meets primary goal
Eli Lilly’s MONARCH 3 trial has met its primary endpoint of demonstrating statistically significant improvement in progression-free survival (PFS).
April 24, 2017
Stada welcomes new managing director
STADA Arzneimittel AG has appointed Dr. Ralph Grobecker as Managing Director at STADA GmbH.
April 24, 2017
Tiziana testing drug for fifth most common cancer
Tiziana Life Sciences a cancer drugs making focused clinical stage biotechnology company got approval in Israel to start testing inhibitor of cell cycle dependent kinases (CDKs), milciclib in a phase II clinical trial.
April 24, 2017
Amryt starts patient testing for rare skin disease
Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has enroled first patient into “EASE”, the company’s pivotal Phase 3 clinical trial, which is evaluating AP101 as a potential treatment for the rare, genetic skin disorder, Epidermolysis Bullosa (“EB”).
April 24, 2017
EU drugmakers urge June decision on new location for watchdog
Europe’s drugmakers pushed for a decision as early as June on the new location for the headquarters of the bloc’s medicines watchdog, which will relocate from London after Britain’s decision to leave the EU.
April 24, 2017
CHMP gives positive opinion for Sanofi’s and Regeneron’s rheumatoid arthritis drug
European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Sanofi and Regeneron Pharmaceuticals joint developed product Kevzara (sarilumab), recommending its approval for use in adult patients with moderately to severely active rheumatoid arthritis.
April 24, 2017
BD buys Bard, appoints new president
BD (Becton, Dickinson and Company) will acquire Bard, a medical technology company focused on vascular, urology, oncology and surgical specialty products for $24 billion and appoint Tom Polen as new president of BD.
April 21, 2017
Teva’s new asthma inhaler poses first cometition for GSK’s Adavir
Teva Pharmaceutical Industries on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline’s best-selling Advair.
April 20, 2017
Mylan launches its generic schizophrenia drug
Mylan has launched of Perphenazine Tablets USP, a generic version of Schering’s Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg.